Cannabis and cannabinoids in Switzerland

Global business and regulatory news covering the cannabis industry

20th May 2024

The long road to EFSA authorisation for CBD as novel food in the European Union

12th April 2024

The uncertain fate of IHDCs in Europe: could a general ban be on the horizon?

17th July 2023

Is the cannabis sector failing to ensure gender equality at its own expense?

More News analysis

Daily regulatory updates of legal changes in the cannabis sector, including monthly compilations

13th December 2024: Switzerland: The city of Bern has extended the service contract for the recreational cannabis pilot project study from 2024 to mid-2027. Since April 2024, 700 participants have been able to purchase cannabis products in selected pharmacies as part of the study, which aims to examine the effects of a combined sales and counselling intervention on users’ behaviour and health. The scientific findings are intended to contribute to the discussion about a future cannabis policy.
2nd December 2024: Switzerland: The Basel cantonal health department has extended the pilot project for the sale of recreational cannabis in pharmacies until January 2027, initially programmed to finish in July 2025. In addition to flowers and hashish, the project will be extended to include lower-risk products: two e-liquids and two tinctures. The project will also offer drug testing of cannabis purchased on the illicit market.
6th November 2024: Switzerland: The Federal Department of Home Affairs is amending Annex 6 of the Narcotics List Ordinance to include synthetic cannabinoids. Industrial and scientific use is excluded. Substances in Annex 6 are treated as narcotics, which means that trade, production and use are illegal. The amendment is already in force.
9th September 2024: Switzerland: The city of Zurich has published a media release on the one-year anniversary of Züri Can, the pilot project for the distribution of recreational cannabis in the city. To date, the project has about 2,100 participants and 21 dispensaries and has made around 36,000 sales. After feedback from participants, four new flower products will be introduced for the second year of sales – which will make 13 cannabis products available in total.
4th July 2024: Switzerland: An initial evaluation of the legal distribution of recreational cannabis as a pilot project in Basel, known as the Grashaus Projects study, has shown that participants have increasingly used lower-risk products such as vapes and edibles compared to smoking, press reports. In addition, participants said they had consumed significantly less cannabis from illegal sources since the start of the study.
2nd May 2024: Switzerland: A popular initiative has been submitted to the Swiss Federal Chancellery to amend the constitution by adding a new article legalising the cultivation, possession and personal use of recreational cannabis. The amendment includes the commercialisation and sale with a licence and allows the home cultivation of 50 cannabis plants and storage of up to 3 kg. According to the press, 40 members of the National Council from all parliamentary groups were among the signatories of the initiative. The committee established for the initiative must collect 100,000 signatures by 30th October 2025, to be analysed by the Federal Council.
10th April 2024: Switzerland: The city of Lucerne has started to register participants in the pilot project for the sale of recreational cannabis. Participants will be able to obtain cannabis products such as flower, hashish, e-liquids and tinctures, which have been specially produced for the study, tested in laboratories and packaged in neutral packaging, from designated pharmacies for a maximum of 24 months. Sales of the products are expected to begin in summer 2024.
8th April 2024: Switzerland: This week, the recreational cannabis project starts in the city of Bern. Around 700 study participants will take part in the project and will be able to buy cannabis in selected pharmacies. The products available include flowers, resins, sprays and e-liquids. The study will examine the effects of a combined sales and counselling intervention on users’ behaviour and health, and the resulting scientific evidence will contribute to the debate on future cannabis policy in Switzerland.
26th March 2024: Switzerland: The canton of Basel-Stadt has published the first results of the pilot project for the sale of cannabis for non-medical purposes, which started in January 2023. A total of 378 people were involved in the project and 41 kg of cannabis was sold in pharmacies. In addition to the flower and hash products available, 67% of participants said they wanted other products such as edibles, THC oil and e-liquids. The head of the project said: "Overall, no incidents and no increase in cannabis use were found during the first year of the study". The study will last until July 2025 and a final report will be prepared for a future discussion on a national cannabis policy.
19th March 2024: Switzerland: The Federal Office of Public Health (FOPH) has given its approval to the canton of Zurich to sell recreational cannabis as a pilot project, media reports. Allegedly, it would be the largest study to date carried out in the country, with 5,000 participants over five years. Sales will be allowed in specialist shops and pharmacies in seven municipalities from May 2024. The aim of the study is to examine the economic and social effects of cannabis legalisation. Other similar pilot projects have already been launched in the cities of Zurich, Basel and Lausanne, as well as in the cantons of Basel-Stadt, Geneva and Basel-Landschaft.
18th March 2024: Switzerland: The University of Zurich has published the first results of the Züri Can project, one of the pilot projects for the sale of cannabis for non-medical purposes, which started on 22nd August 2023. The results show that 21 outlets were available (10 pharmacies, 10 cannabis clubs and 1 drug information centre), 1,928 people participated in the project, and 16,500 sales of flower and hashish were made.
12th December 2023: Switzerland: Following the approval by the Federal Office of Public Health (FOPH) in October 2023 to carry out pilot projects for the controlled distribution of recreational cannabis, the first of two cannabis dispensaries has opened in the municipality of Allschwil. It is said to be the first legal cannabis shop in Europe, and 3,950 people are participating in the project. The prices of cannabis flowers vary between CHF8 (€8) and CHF12 (€12), depending on THC content. Other pilot projects, such as those in Zurich and Basel-Stadt, have already been approved by the FOPH and products have been sold in pharmacies.

Full-length in-depth reports with detailed data and analysis for individual markets around the world

18th September 2024

Switzerland: medical cannabis snapshot, September 2024

25th August 2023

Switzerland: medical cannabis snapshot, August 2023

16th May 2023

Intoxicating hemp-derived cannabinoids: the European online market

More Market reports

Regulatory reports

Comprehensive legal reports outlining how the sector is regulated, interpretation of the laws and relevant bodies

4th November 2024

European recreational cannabis models and commercial opportunities

18th September 2024

Switzerland: medical cannabis snapshot, September 2024

25th August 2023

Switzerland: medical cannabis snapshot, August 2023

More Regulatory reports

Up-to-date information and insights on brands, pricing and retail across selected markets

8th October 2024

Medical cannabis database

21st September 2023

Switzerland CBD insights dashboard, 2023

6th April 2023

Switzerland: online retailer status, Q1 2023

More Market data

Regulatory databases

Regularly updated global regulations currently in place, compiled into easy-to-read maps and tables

3rd December 2024

Regulatory tracker: current global regulation of recreational cannabis

3rd December 2024

Regulatory tracker: current global regulation of medical cannabis

4th November 2024

CannIntelligence policy tracker

More Regulatory databases

Sign up to our newsletter

Stay up-to-date with key market trends and regulatory news and receive complimentary data on a regular basis.

"*" indicates required fields

Corporate Email*

Name*

Comments

This field is for validation purposes and should be left unchanged.